Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer

Wang,Kai; Guan,Chenan; Fang,Chenyan; Jin,Xiaoxiao; Yu,Junhui; Zhang,Yuquan; Zheng,Lingzhi

doi:10.3892/ol.2018.7899

Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer

Authors:
- Kai Wang
- Chenan Guan
- Chenyan Fang
- Xiaoxiao Jin
- Junhui Yu
- Yuquan Zhang
- Lingzhi Zheng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China, Department of Kidney Internal Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: January 29, 2018 https://doi.org/10.3892/ol.2018.7899
Pages: 4457-4462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Forkhead box (FOX) A1 is a member of the FOX family of transcription factors, which serve a function in numerous types of tumor. The present study assessed the potential role of FOXA1 in human epithelial ovarian carcinoma (EOC). Total RNA was isolated from 16 fresh‑frozen EOC tumors with paired corresponding non‑malignant ovarian epithelium tissues, and FOXA1 expression was analyzed using reverse transcription‑quantitative polymerase chain reaction. Immunohistochemical analysis was performed to evaluate FOXA1 expression in 110 epithelial ovarian carcinoma tissue specimens (including 80 serous papillary adenocarcinoma, 9 clear cell carcinoma, 12 endometrioid adenocarcinoma, 5 mucinous carcinoma and 4 transitional cell carcinoma specimens), 24 benign ovarian tumor surface epithelium tissues and 10 normal ovarian tissue samples. The present study analyzed the association between FOXA1 expression and clinical characteristics in patients with EOC. The Kaplan‑Meier method was used for survival analysis. The results of the present study revealed that FOXA1 mRNA expression was significantly increased in EOC tissues compared with paired normal ovarian samples (P=0.014). The immunohistochemical expression of FOXA1 in EOC tissues was associated with the FIGO grade, differentiation status and overall survival time (all P<0.05). Finally, the significance of FOXA1 expression in the prognosis of the patients was evaluated. The results of Kaplan‑Meier survival curve revealed that high FOXA1 expression was associated with decreased overall survival time in the patients, relative to low FOXA1 expression (P=0.0132). In conclusion, FOXA1 is overexpressed in EOC and associated with clinicopathological features, including overall survival time. FOXA1 potentially represents a novel biomarker and therapeutic target for EOC.

View Figures

View References

1	Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC: Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ozols RF: Treatment goals in OC. Int J Gynecol Cancer. 15 Suppl 1:S3–S11. 2005. View Article : Google Scholar
5	Schink JC: Current initial therapy of stage III and IV OC: challenges for managed care. Semin Oncol. 26(1 Suppl 1): S2–S7. 1999.
6	Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279. 2002.PubMed/NCBI
7	Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY and Koeffler HP: FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer. 120:1013–1022. 2007. View Article : Google Scholar : PubMed/NCBI
8	Lantz KA and Kaestner KH: Winged-helix transcription factors and pancreatic development. Clin Sci (Lond). 108:195–204. 2005. View Article : Google Scholar : PubMed/NCBI
9	Costa RH, Grayson DR and Darnell JE Jr: Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol. 9:1415–1425. 1989. View Article : Google Scholar : PubMed/NCBI
10	Lai E, Prezioso VR, Smith E, Litvin O, Costa RH and Darnell JE Jr: HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. Genes Dev. 4:1427–1436. 1990. View Article : Google Scholar : PubMed/NCBI
11	Carroll JS and Brown M: Estrogen receptor target gene: An evolving concept. Mol Endocrinol. 20:1707–1714. 2006. View Article : Google Scholar : PubMed/NCBI
12	Friedman JR and Kaestner KH: The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci. 63:2317–2328. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lee CS, Friedman JR, Fulmer JT and Kaestner KH: The initiation of liver development is dependent on Foxa transcription factors. Nature. 435:944–947. 2005. View Article : Google Scholar : PubMed/NCBI
14	Besnard V, Wert SE, Hull WM and Whitsett JA: Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr Patterns. 5:193–208. 2004. View Article : Google Scholar : PubMed/NCBI
15	Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M and Zaret KS: Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 9:279–289. 2002. View Article : Google Scholar : PubMed/NCBI
16	Gualdi R, Bossard P, Zheng M, Hamada Y, Coleman JR and Zaret KS: Hepatic specification of the gut endoderm in vitro: Cell signaling and transcriptional control. Genes Dev. 10:1670–1682. 1996. View Article : Google Scholar : PubMed/NCBI
17	Nakshatri H and Badve S: FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets. 11:507–514. 2007. View Article : Google Scholar : PubMed/NCBI
18	Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al: FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
19	Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG and Nakshatri H: FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res. 13:4415–4421. 2007. View Article : Google Scholar : PubMed/NCBI
20	Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS and Badve S: Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol. 61:327–332. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS and Brown M: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI
22	Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zeppernick F and Meinhold-Heerlein I: The new FIGO staging system for ovarian, fallopian tube and primary peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hauptmann S, du Bois A, Meinhold-Herlein I, Pfisterer J and Avril S: Histological grading of epithelial ovarian cancer. Review and recommendation. Pathologe. 35:497–503. 2014. View Article : Google Scholar : PubMed/NCBI
25	Vinayagamoorthy T, Maryanski D, Vinayagamoorthy D, Hay KS, Yo J, Carter M and Wiegel J: Improved internal control for molecular diagnosis assays. MethodsX. 2:159–164. 2015. View Article : Google Scholar : PubMed/NCBI
26	Kaestner KH, Knochel W and Martinez DE: Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 14:142–146. 2000.PubMed/NCBI
27	Lehmann OJ, Sowden JC, Carlsson P, Jordan T and Bhattacharya SS: Fox's in development and disease. Trend Genet. 19:339–344. 2003. View Article : Google Scholar
28	Tan Y, Raychaudhuri P and Costa RH: Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 27:1007–1016. 2007. View Article : Google Scholar : PubMed/NCBI
29	Robinson JL and Carroll JS: FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Front Endocrinol (Lausanne). 3:682012.PubMed/NCBI